Targeted drug combo shows promise for rare BRAF-Mutated cancers
NCT ID NCT04439292
First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 31 times
Summary
This study tests two targeted drugs, dabrafenib and trametinib, in people with advanced cancers that have a specific BRAF gene mutation (V600E or V600K). The goal is to see if the combination can shrink tumors or stop them from growing. About 44 adults with various cancer types (excluding melanoma, thyroid, colorectal, and lung cancers) are taking part. The treatment is not a cure but aims to control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
ECOG-ACRIN Cancer Research Group
Philadelphia, Pennsylvania, 19103, United States
Conditions
Explore the condition pages connected to this study.